ACM
ESPR

Advent Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Advent Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$370K – 223
2025
Q4 		$370K Buy
+100,000
New +$323K 0.01% 210

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Advent Capital Management's ESPR Position: Q2 2026 in Review

Advent Capital Management sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 50,000 shares — an estimated $137K sold.

Advent Capital Management first reported a position in ESPR in Q3 2025 and held it in 3 quarters. The position peaked at $333K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Advent Capital Management reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Advent Capital Management sold 50,000 Esperion Therapeutics shares in Q2 2026, an estimated $137K.
  • Advent Capital Management first reported a position in Esperion Therapeutics in Q3 2025 and held it in 3 quarters.
  • Advent Capital Management's Esperion Therapeutics position peaked at $333K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Advent Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.